<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980148</url>
  </required_header>
  <id_info>
    <org_study_id>07-0012</org_study_id>
    <nct_id>NCT00980148</nct_id>
  </id_info>
  <brief_title>Treatment Failure of Chlamydial Infection in Males and Females in Youth Correctional Facilities</brief_title>
  <official_title>Randomized Clinical Trial Evaluating Treatment Failure Following Recommended Therapy (Azithromycin Versus Doxycycline) for Genital Chlamydial Infection in Males and Females in Youth Correctional Facilities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Chlamydia is a common infection among youth and can be given from one person to another
      during sex. Many people who have chlamydia have no signs of infection at all, but can pass
      the infection to anyone they have sex with. If not treated, chlamydia can lead to serious
      health problems. This study will look at how well medicines given for chlamydia infection
      work. The study requires 306 evaluable subjects, chlamydia-positive, males and non-pregnant
      females, ages 12-21, living in long-term, gender-segregated youth correctional facilities.
      Participants will be assigned to receive either doxycycline (2 times per day, by mouth, for 7
      days) or azithromycin (1 single dose by mouth). Study procedures will include collection of
      at least 3 urine samples to test for chlamydia. Study visits will occur during initial
      enrollment in the study, day 28 after starting treatment, and day 67. Participants will be
      involved in study related procedures for up to 67 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Genital chlamydia is a public health concern. The World Health Organization (WHO) estimates
      that 90 million of all new cases of sexually transmitted diseases (STDs) per year are caused
      by Chlamydia (C.) trachomatis. In the United States alone, approximately 3 million new cases
      of chlamydia are reported yearly, and the costs associated with their management and
      complications exceed $2 billion. Unfortunately, at least 75 percent of females with chlamydia
      are asymptomatic, and unless the infection is detected through chlamydia testing (screening),
      their infection may be transmitted to others or lead to complications. The Centers of Disease
      Control and Prevention (CDC) recommends either azithromycin 1 gram (gm) by mouth (PO) once or
      doxycycline 100 milligrams (mg) PO twice daily (BID) for 7 days as co-equal therapies for
      uncomplicated chlamydia. A secondary aim will be to determine demographic predictors of
      chlamydia treatment failure following azithromycin or doxycycline treatment, and to explore
      clinical parameters, which distinguish those with persistent infection. The study design of
      this Phase III trial will address major limitations of prior chlamydia efficacy studies and
      the findings will reveal both the true efficacy of azithromycin and doxycycline in
      uncomplicated chlamydia in adolescents and the factors that predict treatment failure. This
      study is designed primarily to determine the frequency of chlamydia treatment failure
      following either azithromycin or doxycycline regimens and to evaluate whether the efficacy of
      the azithromycin regimen is inferior to the doxycycline regimen. Both drugs are Food and Drug
      Administration (FDA) approved for use in the U.S. The study will enroll 650 males and females
      age 12-21 years in good health (based on vital signs and provider's clinical evaluation
      documented in medical records) who are residing in long-term gender-segregated (not co-ed)
      youth correctional facilities (YCFs) (usual stay &gt;3 weeks) and who are identified as
      chlamydia-infected would comprise the study population until 306 evaluable subjects are
      obtained . Only individuals who have a positive chlamydia screening test are enrolled, and
      those with negative screening tests are excluded. Consenting chlamydia-positive subjects at
      the enrollment visit (study visit 1) will be enrolled, asked to provide demographic data, to
      provide a first-void urine sample (not a mid-stream specimen) for repeat chlamydia testing
      with Gen-Probe (GP) AC2 (for verification of chlamydia), and then randomized to 1 of 2
      treatment arms (190 153 subjects per arm): doxycycline 100 mg PO BID for 7 days or
      azithromycin 1 gm PO single dose. Both therapies are given as directly observed, and side
      effects are evaluated at the first follow-up visit (day 28 after study drug initiation). If a
      subject who's GP AC2 from the enrollment treatment visit returns negative for C. trachomatis,
      they will be categorized as unevaluable and will be removed from the study, then the site
      investigator will determine whether the subject will complete this treatment or will receive
      other therapy. Subjects whose GP AC2 at the enrollment treatment visit is positive for C.
      trachomatis will then be asked to provide a first-void urine sample for repeat chlamydia
      testing with GP AC2 at 28- and 67-days after study drug initiation [corresponding to the
      first follow-up visit (study visit 2) and second follow-up visit (study visit 3),
      respectively].
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess Microbiological Failure of Recommended Azithromycin and Doxycycline Regimens in Uncomplicated Chlamydia Trachomatis Infection in a Setting Where Repeat Exposure to Chlamydia-infected Persons Can be Minimized.</measure>
    <time_frame>Study visit # 2 (Day 28 after therapy started)</time_frame>
    <description>The proportion of participants with testing by Gen-Probe Aptima Combo 2 that is positive for C. trachomatis and C. trachomatis OmpA (Major Outer Membrane Protein) genotyping reveals the baseline chlamydial strain and the repeat positive chlamydial strain to be the same genotype (i.e., concordant).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demographical Characteristics and Clinical Parameters to Predict Treatment Outcome.</measure>
    <time_frame>Baseline and study visit #2 (Day 28 after therapy is started)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">567</enrollment>
  <condition>Chlamydial Infection</condition>
  <arm_group>
    <arm_group_label>Arm2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxycycline 100 mg oral twice a day (BID) for 7 days; 153 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azithromycin 1 gm oral single dose; 153 subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>FDA approved, a 1 gm single dose, two 500 mg tablets.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>FDA approved, a 100 mg capsule twice a day for 7 days.</description>
    <arm_group_label>Arm2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between the ages of 12 and 21 years

          -  Residing in a long-term gender-segregated (no co-ed) youth correctional facility (YCF)

          -  Diagnosed with genital chlamydia as determined by a screening C. trachomatis nucleic
             acid amplification test (NAAT)

          -  Anticipated length of stay at the YCF at the time of enrollment is &gt; 3 weeks

          -  Willingness to provide written consent

          -  Willingness to comply with study procedures

        Exclusion Criteria:

          -  Diagnosed with gonorrhea as determined by a screening Neisseria gonorrhoeae nucleic
             acid amplification test (NAAT)

          -  Clinical diagnosis of pelvic inflammatory disease (PID) or epididymitis based on
             review of medical records

          -  Known allergy to tetracyclines or macrolides

          -  Currently pregnant or breastfeeding

          -  History of photosensitivity related to doxycycline use

          -  Having received antimicrobial therapy with activity against C. trachomatis within 21
             days of the positive chlamydia screening NAAT or in the interval between the positive
             screening NAAT and study enrollment

          -  Any concomitant infection, which requires antimicrobial therapy with activity against
             C. trachomatis

          -  Previously enrolled in this study

          -  Unable to swallow pills

          -  Other exclusion criteria, per clinician judgment, that prohibits subject from
             enrolling in study

          -  Of note, current use of oral contraceptive agents (OCPs) is not an exclusion criterion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama Hospital - Infectious Diseases</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles County Department of Public Health - Sexually Transmitted Disease Program</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007-2608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2009</study_first_submitted>
  <study_first_submitted_qc>September 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2009</study_first_posted>
  <results_first_submitted>March 5, 2015</results_first_submitted>
  <results_first_submitted_qc>March 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 18, 2015</results_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chlamydia trachomatis, Chlamydia, Doxycycline, Azithromycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Chlamydia Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Azithromycin Arm</title>
          <description>Azithromycin 1 gm oral single dose</description>
        </group>
        <group group_id="P2">
          <title>Doxycycline Arm</title>
          <description>Doxycycline 100 mg oral twice a day for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="284"/>
                <participants group_id="P2" count="283"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="155">Completed primary evaluation at study visit # 2 (day 28 after therapy started)</participants>
                <participants group_id="P2" count="155">Completed primary evaluation at study visit # 2 (day 28 after therapy started)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="128"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discharged from facility</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Received other antichlamydia treatment</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Negative for chlamydia at enrollment</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Various other reasons</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The per protocol population is comprised of participants who completed therapy and whose failure status could be established at the day 28 visit. Participants were considered to have completed therapy if they took a single dose of azithromycin or at least 10 of the 14 doses of doxycycline.</population>
      <group_list>
        <group group_id="B1">
          <title>Azithromycin Arm</title>
          <description>Azithromycin 1 gm oral single dose</description>
        </group>
        <group group_id="B2">
          <title>Doxycycline Arm</title>
          <description>Doxycycline 100 mg oral twice a day for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="155"/>
            <count group_id="B2" value="155"/>
            <count group_id="B3" value="310"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.0" spread="0.9"/>
                    <measurement group_id="B2" value="16.8" spread="1.1"/>
                    <measurement group_id="B3" value="16.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assess Microbiological Failure of Recommended Azithromycin and Doxycycline Regimens in Uncomplicated Chlamydia Trachomatis Infection in a Setting Where Repeat Exposure to Chlamydia-infected Persons Can be Minimized.</title>
        <description>The proportion of participants with testing by Gen-Probe Aptima Combo 2 that is positive for C. trachomatis and C. trachomatis OmpA (Major Outer Membrane Protein) genotyping reveals the baseline chlamydial strain and the repeat positive chlamydial strain to be the same genotype (i.e., concordant).</description>
        <time_frame>Study visit # 2 (Day 28 after therapy started)</time_frame>
        <population>The per protocol population is comprised of participants who completed therapy and whose failure status could be established at the day 28 visit. Participants were considered to have completed therapy if they took a single dose of azithromycin or at least 10 of the 14 doses of doxycycline.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin Arm</title>
            <description>Azithromycin 1 gm oral single dose</description>
          </group>
          <group group_id="O2">
            <title>Doxycycline Arm</title>
            <description>Doxycycline 100 mg oral twice a day for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Microbiological Failure of Recommended Azithromycin and Doxycycline Regimens in Uncomplicated Chlamydia Trachomatis Infection in a Setting Where Repeat Exposure to Chlamydia-infected Persons Can be Minimized.</title>
          <description>The proportion of participants with testing by Gen-Probe Aptima Combo 2 that is positive for C. trachomatis and C. trachomatis OmpA (Major Outer Membrane Protein) genotyping reveals the baseline chlamydial strain and the repeat positive chlamydial strain to be the same genotype (i.e., concordant).</description>
          <population>The per protocol population is comprised of participants who completed therapy and whose failure status could be established at the day 28 visit. Participants were considered to have completed therapy if they took a single dose of azithromycin or at least 10 of the 14 doses of doxycycline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This noninferiority study tested the null hypothesis that the failure rate of azithromycin is 5% higher than that of doxycycline against the alternative hypothesis that there is no difference between the two treatments. The one-sided 90% exact confidence interval was used to estimate the difference between the two failures rates.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This noninferiority study tested the null hypothesis that the failure rate of azithromycin is 5% higher than that of doxycycline against the alternative hypothesis that there is no difference between the two treatments. The treatment failure rate was assumed to be 3% for both treatments. To test this hypothesis at the one-sided 0.10 significance level with power of 0.90 required 153 study subjects per arm in the per-protocol population.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>3.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>5.9</ci_upper_limit>
            <estimate_desc>The risk difference is the percentage in the azithromycin arm with treatment failure minus the percentage in the doxycycline arm with treatment failure. Noninferiority of azithromycin would be supported if the upper 90% confidence limit is below 5%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Demographical Characteristics and Clinical Parameters to Predict Treatment Outcome.</title>
        <time_frame>Baseline and study visit #2 (Day 28 after therapy is started)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) that occur after study drug administration (Study Visit 1) and through the first follow-up visit (Study Visit 2, Day 28) were recorded. AEs were followed until resolution even if this extended beyond the study-reporting period.</time_frame>
      <desc>Resolution of an AE is defined as the return to pretreatment status or stabilization of the condition with the expectation that it will remain chronic. In Sept 2010, the protocol was amended to streamline reportable AEâ€™s by limiting to GI related symptoms, vaginal irritation or itching, and dermatologic reactions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Azithromycin Arm</title>
          <description>Azithromycin 1 gm oral single dose</description>
        </group>
        <group group_id="E2">
          <title>Doxycycline Arm</title>
          <description>Doxycycline 100 mg oral twice a day for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The analysis of the secondary endpoint Demographical Characteristics and Clinical Parameters to Predict Treatment Outcome was limited by the small number of events and is not presented.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Shelly Lensing, Statistician</name_or_title>
      <organization>University of Arkansas for Medical Sciences</organization>
      <phone>501-686-8203</phone>
      <email>sylensing@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

